Dr. Stephen Carrithers is the founder and CEO of AmDx PrognostX, a biotechnology company working to develop an immunoassay blood test to identify early diabetes-related microvascular dysfunction. With 88 million Americans suffering from prediabetes, many remain unaware of their condition, leaving them at risk for developing type 2 diabetes and other serious health complications. The groundbreaking test by AmDx PrognostX aims to predict which prediabetic patients will progress into kidney disease and allow for proactive and preventative treatment.

In this episode, we discuss the challenges faced by prediabetic patients, the importance of early detection and intervention, and the unique family dynamic at AmDx PrognostX, which combines the expertise of MBAs, MDs, and PhDs. We also explore the company's recent successes, including receiving an SBIR Phase II grant from the NIH and their plan to bring the diagnostic test to market.

Learn more about AmDx PrognostX at PrognostXHealth.com.

Visit us at ⁠⁠⁠⁠MiddleTech.com⁠⁠⁠⁠

Follow Us

⁠⁠⁠⁠Twitter⁠⁠⁠⁠

⁠⁠⁠⁠Instagram⁠⁠⁠⁠

⁠⁠⁠⁠Facebook⁠⁠⁠⁠

⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠

⁠⁠⁠⁠Logan's Twitter⁠⁠⁠⁠

⁠⁠⁠⁠Evan's Twitter⁠⁠⁠⁠